<DOC>
	<DOCNO>NCT01766817</DOCNO>
	<brief_summary>The purpose study determine study drug ( BMS-986020 ) dose 600 mg daily 600 mg twice daily 26 week compare placebo reduce decline force vital capacity ( FVC ) well tolerated subject idiopathic pulmonary fibrosis ( IPF ) .</brief_summary>
	<brief_title>Safety Efficacy Lysophosphatidic Acid Receptor Antagonist Idiopathic Pulmonary Fibrosis</brief_title>
	<detailed_description />
	<mesh_term>Fibrosis</mesh_term>
	<mesh_term>Pulmonary Fibrosis</mesh_term>
	<mesh_term>Idiopathic Pulmonary Fibrosis</mesh_term>
	<mesh_term>Idiopathic Interstitial Pneumonias</mesh_term>
	<criteria>Are age 40 90 year , inclusive , randomization . Have clinical symptom consistent IPF . Have first receive diagnosis IPF le 6 year randomization . The date diagnosis define date first available image surgical lung biopsy consistent IPF/UIP . Have diagnosis usual interstitial pulmonary fibrosis ( UIP ) IPF HRCT surgical lung biopsy ( SLB ) . Extent fibrotic change ( honeycomb , reticular change ) great extent emphysema HRCT scan . Have feature support alternative diagnosis transbronchial biopsy , BAL , SLB , perform . Have percent predict postbronchodilator FVC 45 % 90 % , inclusive , screen . Have change postbronchodilator FVC ( measure liter ) screen day 1 less 10 % relative difference , calculate : absolute value 100 % * ( screen FVC ( L ) day 1 FVC ( L ) ) / screen FVC ( L ) . Have carbon monoxide diffuse capacity ( DLCO ) 30 % 80 % ( adjust hemoglobin altitude ) , inclusive , screen . Have evidence improvement measure IPF disease severity precede year , investigator 's opinion . Be able walk 150 meter screen . Demonstrate exertional decrease oxygen saturation 2 percentage point great screen ( may perform supplemental oxygen titrate keep oxygen saturation level &gt; 88 % ) . Are able understand sign write informed consent form . Are able understand importance adherence study treatment study protocol willing comply study requirement , include concomitant medication restriction , throughout study . Women childbearing potential ( WOCBP ) men sexually active WOCBP must use acceptable method ( ) contraception . The individual method contraception duration determine consultation investigator . WOCBP must follow instruction birth control halflife investigational drug le 24 hour , contraception continue period 30 day last dose investigational product . 1 . Women must negative urine pregnancy test within 24 hour prior start investigational product . 2 . Women must breastfeed . 3 . Men sexually active WOCBP must use contraceptive method failure rate le 1 % per year . Men sexually active WOCBP must follow instruction birth control halflife investigational drug le 24 hour , contraception continue period 90 day last dose investigational product . 4 . Women childbearing potential ( i.e. , postmenopausal surgically sterile ) azoospermic men require contraception . Target Disease Exclusions 1 . Has significant clinical worsen IPF screen day 1 ( screen process ) , opinion investigator . 2 . Has force expiratory volume 1 second ( FEV1 ) /FVC ratio le 0.8 administration bronchodilator screen . 3 . Has bronchodilator response , define absolute increase 12 % great increase 200 mL FEV1 FVC bronchodilator use compare value bronchodilator use screening . Medical History Concurrent Diseases 1 . Has history clinically significant environmental exposure know cause pulmonary fibrosis , include , limited , drug ( amiodarone ) , asbestos , beryllium , radiation , domestic bird . 2 . Has know explanation interstitial lung disease , include , limited , radiation , drug toxicity , sarcoidosis , hypersensitivity , pneumonitis , bronchiolitis , obliterans , organize pneumonia , human immunodeficiency virus ( HIV ) , viral hepatitis , cancer . 3 . Has clinical diagnosis connective tissue disease , include , limited , scleroderma , polymyositis/dermatomyositis , systemic lupus erythematosus , rheumatoid arthritis , undifferentiated connective tissue disease . 4 . Currently clinically significant asthma chronic obstructive pulmonary disease . 5 . Has clinical evidence active infection , include , limited , bronchitis , pneumonia , sinusitis , urinary tract infection , cellulitis . 6 . Has history malignancy likely result significant disability likely require significant medical surgical intervention within next 2 year . This include minor surgical procedure localize cancer ( e.g. , basal cell carcinoma ) . 7 . Has condition IPF , opinion investigator , likely result death subject within next 2 year . 8 . Has history endstage liver disease . 9 . Has history endstage renal disease require dialysis . 10 . Has history unstable deteriorate cardiac pulmonary disease ( IPF ) within previous 6 month , include , limited , follow : i. Unstable angina pectoris myocardial infarction ii . Congestive heart failure require hospitalization iii . Uncontrolled clinically significant arrhythmias 11 . Has condition , opinion investigator , might significantly exacerbate know side effect associate administration BMS986020 . 12 . Has history alcohol substance abuse past 2 year . 13 . Has family personal history long QT syndrome and/or Torsades de Pointes ( polymorphic ventricular tachycardia ) . 14 . Has use exclude medication per Appendix 1 Protocol , include , limited : current treatment pirfenidone nintedanib use overthecounter medication herbal preparation , within 4 week study drug administration except medication clear BMS medical monitor For subject take statin , restriction maximum allowable dos statin list . If subject currently take statin dose high mention , please reduce dose maximum allowable dose . Additionally , subject statins ready start dosing , subject limit statin dose maximal allowable dose lower least 5 day prior first BMS986020 dosing . Shorter duration may consider select case discussion medical monitor . Maximum allowable dose statin : Simvastatin 20 mg QD Pitavastatin 2 mg QD Atorvastatin 40 mg QD Pravastatin 40 mg QD Rosuvastatin 20 mg QD Lovastatin 40 mg QD Fluvastatin 40 mg QD Prednisone allow maximum 15 mg po daily Pirfenidone nintedanib dose maximum 3 month prior 12 month permit 4 week washout period prior dose BMS986020 . Physical Laboratory Test Findings 1 . Has follow liverfunction test criterion specify limit : total bilirubin &gt; 1.5 x ULN , exclude subject Gilbert 's syndrome ; aspartate alanine aminotransferase ( AST/SGOT ALT/SGPT ) great 3 x ULN ; alkaline phosphatase great 2.5 x ULN . 2 . Has creatinine clearance le 30 mL/minute , calculate use CockcroftGault formula . 3 . Has ECG result QT interval Fridericia 's correction ( QTcF ) 500 msec great uncorrected QT 500 msec great screening . Note : For subject machine read QT interval &gt; 500 msec , heart rate &gt; 100 bpm , machine read QT interval ( either correct ) may accurate . If investigator uncertain QT abnormality , recommend ECGs overread cardiologist . The manually read QT interval cardiologist use assessment eligibility whenever possible . Allergies Adverse Drug Reaction Has prior use BMS986020 know hypersensitivity component study treatment . Other Exclusion Criteria 1 . Is suitable candidate enrollment unlikely comply requirement study , opinion investigator . 2 . Has smoke cigarette within 4 week screen unwilling avoid tobacco product throughout study . 3 . Is expect receive lung transplant within 1 year randomization , subject site United States , lungtransplant wait list screening . 4 . Prisoners subject involuntarily incarcerate . 5 . Subjects compulsorily detain treatment either psychiatric physical ( e.g. , infectious disease ) illness . 6 . Inability comply restriction prohibit activities/treatments list Section 3.3 Protocol .</criteria>
	<gender>All</gender>
	<minimum_age>40 Years</minimum_age>
	<maximum_age>90 Years</maximum_age>
	<verification_date>July 2016</verification_date>
	<keyword>IPF</keyword>
</DOC>